Case Report: Contrast-enhanced ultrasonography for evaluating a newly detected contralateral pulmonary lesion during non-small cell lung cancer chemoimmunotherapy - Takeaways - MDSpire

Case Report: Contrast-enhanced ultrasonography for evaluating a newly detected contralateral pulmonary lesion during non-small cell lung cancer chemoimmunotherapy

  • By

  • Yang Liu

  • Lusi Feng

  • Xiaoqian Yang

  • Shiyu Wen

  • Yu Xiang

  • Xuelei Ma

  • Rongxing Zhou

  • Wei Du

  • May 21, 2026

Share

  • 1

    New pulmonary lesions during chemoimmunotherapy for NSCLC can indicate tumor progression, infection, or benign processes, complicating diagnosis.

  • 2

    Contrast-enhanced ultrasonography (CEUS) provides real-time perfusion information, aiding in the characterization of peripheral pulmonary lesions.

  • 3

    In a case study, CEUS suggested an inflammatory nature for a newly detected contralateral lesion in a patient undergoing NSCLC treatment.

  • 4

    The interpretation of CEUS findings was supported by microbiologic evidence of infection and confirmed by lesion regression after treatment.

  • 5

    CEUS is most effective when combined with clinical, laboratory, microbiologic, and imaging data, rather than used alone for diagnosis.

Original Source(s)

Case Report: Contrast-enhanced ultrasonography for evaluating a newly detected contralateral pulmonary lesion during non-small cell lung cancer chemoimmunotherapy

  • by Yang Liu, Lusi Feng, Xiaoqian Yang, Shiyu Wen, Yu Xiang, Xuelei Ma, Rongxing Zhou, Wei Du

  • May 21, 2026

Related Content

Turning Medical Insights into Patient Impact

Veeva research reveals a stark gap between the insights biopharma captures and the actions it takes – highlighting a missed opportunity to improve patient outcomes

Rethinking Progress in Clinical Trials

Three clinical development leaders discuss how early signals, trial design, regulatory expectations, and patient access are reshaping clinical development

  • May 20, 2026

  • 11 min
Roswell Park Experts Report on Discovery of Rare Bladder Cells, Neural Mapping of Pelvic Floor Muscles at AUA 2026

Evidence provided by a Roswell Park study indicates that neoadjuvant chemotherapy may be the preferred course of treatment for patients with non-muscle-invasive bladder cancer (NMIBC) when their disease progresses and they are diagnosed with muscle-invasive bladder cancer (MIBC)

  • by

  • May 19, 2026

  • 7 min